File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine

TitleMaternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine
Authors
Keywords9vHPV vaccine
Clinical trial
Geometric mean titers (GMTs)
Human papillomavirus
Recurrent respiratory papillomatosis
Issue Date2019
PublisherTaylor & Francis Inc. The Journal's web site is located at http://www.tandfonline.com/khvi
Citation
Human Vaccines & Immunotherapeutics, 2019, v. 15 n. 1, p. 141-145 How to Cite?
AbstractBackground: This exploratory analysis was conducted to characterize the level of HPV types 6/11 antibodies in peripartum maternal blood and in cord blood of infants born to women who received 9-valent HPV (9vHPV) vaccine or quadrivalent HPV (qHPV) vaccine in a pivotal efficacy study (V503-001, NCT 00543543). Methods: A total of 21 mother-infant pairs had evaluable HPV 6/11 results available for analysis. HPV6/11 antibodies were assessed using competitive Luminex immunoassay. The distribution of the ratios of infant to mother anti-HPV antibodies (i.e., infant-anti-HPV/mother- anti-HPV) was summarized. Results: All mothers and infants were seropositive to HPV 6 and HPV 11. Anti-HPV 6/11 geometric mean titers (GMTs) in peripartum maternal blood and in cord blood of infant born to study participants were highly correlated. A 100% of infants born to seropositive mothers were also seropositive. The GMT ratios of peripartum maternal blood vs. those in cord blood were HPV 6: 1.23 [0.43, 3.49] and HPV 11: 1.29 [0.54, 3.07] in the 9vHPV vaccine group and HPV 6: 1.33 [0.41, 4.29] and HPV 11: 1.19 [0.45, 3.13] in the qHPV vaccine group, respectively. Conclusions: These results indicate that antibodies induced by the 9vHPV vaccine cross the placenta, which could potentially be beneficial against HPV6/11 infection and related disease such as recurrent respiratory papillomatosis.
Persistent Identifierhttp://hdl.handle.net/10722/269483
ISSN
2017 Impact Factor: 2.229
2015 SCImago Journal Rankings: 0.935
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorGuevara, AM-
dc.contributor.authorSuarez, E-
dc.contributor.authorVictoria, A-
dc.contributor.authorNgan, HYS-
dc.contributor.authorHirschberg, AL-
dc.contributor.authorFedrizzi, E-
dc.contributor.authorBautista, O-
dc.contributor.authorShields, C-
dc.contributor.authorJoshi, A-
dc.contributor.authorLuxembourg, A-
dc.date.accessioned2019-04-24T08:08:38Z-
dc.date.available2019-04-24T08:08:38Z-
dc.date.issued2019-
dc.identifier.citationHuman Vaccines & Immunotherapeutics, 2019, v. 15 n. 1, p. 141-145-
dc.identifier.issn2164-5515-
dc.identifier.urihttp://hdl.handle.net/10722/269483-
dc.description.abstractBackground: This exploratory analysis was conducted to characterize the level of HPV types 6/11 antibodies in peripartum maternal blood and in cord blood of infants born to women who received 9-valent HPV (9vHPV) vaccine or quadrivalent HPV (qHPV) vaccine in a pivotal efficacy study (V503-001, NCT 00543543). Methods: A total of 21 mother-infant pairs had evaluable HPV 6/11 results available for analysis. HPV6/11 antibodies were assessed using competitive Luminex immunoassay. The distribution of the ratios of infant to mother anti-HPV antibodies (i.e., infant-anti-HPV/mother- anti-HPV) was summarized. Results: All mothers and infants were seropositive to HPV 6 and HPV 11. Anti-HPV 6/11 geometric mean titers (GMTs) in peripartum maternal blood and in cord blood of infant born to study participants were highly correlated. A 100% of infants born to seropositive mothers were also seropositive. The GMT ratios of peripartum maternal blood vs. those in cord blood were HPV 6: 1.23 [0.43, 3.49] and HPV 11: 1.29 [0.54, 3.07] in the 9vHPV vaccine group and HPV 6: 1.33 [0.41, 4.29] and HPV 11: 1.19 [0.45, 3.13] in the qHPV vaccine group, respectively. Conclusions: These results indicate that antibodies induced by the 9vHPV vaccine cross the placenta, which could potentially be beneficial against HPV6/11 infection and related disease such as recurrent respiratory papillomatosis.-
dc.languageeng-
dc.publisherTaylor & Francis Inc. The Journal's web site is located at http://www.tandfonline.com/khvi-
dc.relation.ispartofHuman Vaccines & Immunotherapeutics-
dc.subject9vHPV vaccine-
dc.subjectClinical trial-
dc.subjectGeometric mean titers (GMTs)-
dc.subjectHuman papillomavirus-
dc.subjectRecurrent respiratory papillomatosis-
dc.titleMaternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine-
dc.typeArticle-
dc.identifier.emailNgan, HYS: hysngan@hkucc.hku.hk-
dc.identifier.authorityNgan, HYS=rp00346-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1080/21645515.2018.1514227-
dc.identifier.pmid30261146-
dc.identifier.pmcidPMC6363163-
dc.identifier.scopuseid_2-s2.0-85053886372-
dc.identifier.hkuros297622-
dc.identifier.volume15-
dc.identifier.issue1-
dc.identifier.spage141-
dc.identifier.epage145-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats